- Home
- SLGN vs GH Comparison
SLGN vs GH Comparison
Compare SLGN & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGN
- GH
- Stock Information
- Founded
- SLGN 1987
- GH 2011
- Country
- SLGN United States
- GH United States
- Employees
- SLGN N/A
- GH N/A
- Industry
- SLGN Containers/Packaging
- GH Medical Specialities
- Sector
- SLGN Industrials
- GH Health Care
- Exchange
- SLGN Nasdaq
- GH Nasdaq
- Market Cap
- SLGN 4.5B
- GH 4.9B
- IPO Year
- SLGN 1997
- GH 2018
- Fundamental
- Price
- SLGN $43.17
- GH $65.46
- Analyst Decision
- SLGN Strong Buy
- GH Strong Buy
- Analyst Count
- SLGN 9
- GH 22
- Target Price
- SLGN $60.11
- GH $64.91
- AVG Volume (30 Days)
- SLGN 1.1M
- GH 2.2M
- Earning Date
- SLGN 10-29-2025
- GH 10-29-2025
- Dividend Yield
- SLGN 1.85%
- GH N/A
- EPS Growth
- SLGN N/A
- GH N/A
- EPS
- SLGN 2.81
- GH N/A
- Revenue
- SLGN $6,162,113,000.00
- GH $828,849,000.00
- Revenue This Year
- SLGN $11.86
- GH $28.30
- Revenue Next Year
- SLGN $2.75
- GH $22.98
- P/E Ratio
- SLGN $15.36
- GH N/A
- Revenue Growth
- SLGN 5.49
- GH 28.74
- 52 Week Low
- SLGN $41.30
- GH $20.14
- 52 Week High
- SLGN $58.14
- GH $68.23
- Technical
- Relative Strength Index (RSI)
- SLGN 48.06
- GH 59.00
- Support Level
- SLGN $41.83
- GH $61.00
- Resistance Level
- SLGN $43.68
- GH $68.22
- Average True Range (ATR)
- SLGN 0.86
- GH 2.50
- MACD
- SLGN 0.23
- GH 0.12
- Stochastic Oscillator
- SLGN 67.42
- GH 64.47
About SLGN Silgan Holdings Inc.
Silgan Holdings manufactures about half of the metal food containers in North America. Its major customers include Campbell Soup, Nestle, and Del Monte. Silgan's other business segments include plastic dispensers and containers for personal and healthcare products and a closures business that manufactures metal and plastic lids and caps.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.